GlassScriptPhysician profile
Lilian Paulla
NPI 1780396382
$2,627.32
in general payments reported to CMS, 2019-2025
15 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $956 · 2024: $1,050 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568 · Education: $59.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.26 |
| Education | $59.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $546.47 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $446.31 | 2023-2024 | Rexulti, Nuedexta, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $375.95 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $245.75 | 2023-2024 | Caplyta |
| Alkermes, INC. | $223.67 | 2024-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $215.15 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $141.52 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $133.84 | 2023-2024 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $83.61 | 2023 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $51.56 | 2023 | |
| Idorsia Pharmaceuticals US INC | $50.18 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $41.96 | 2023 | Qelbree |
| Corium, LLC | $37.55 | 2023 | Azstarys |
| Harmony Biosciences LLC | $19.07 | 2023 | Wakix |
| Ironshore Pharmaceuticals INC. | $14.73 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilian Paulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.